Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSilence Therapeutics PLC

Silence Therapeutics PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
19.73 USD 0.01 ( 0.05%)
Last update at 2026-11-06T21:00:00Z
VOLUME
957992
Market Cap
1030.72M

Momentum Score

…

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
19.71
Low
19.77
High
52 Week Price Range
4.84
Low
27.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
19.72
Dividend Yield
-
Revenue TTM
25.38M
Revenue Per Share
0.68
Gross Profit TTM
6.62M
Debt / Equity
0.02
ROE
-221.19%
Net Debt
-53.76M
ROCE
-63.89%
Diluted EPS TTM
-1.18

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -47.37M -45.86M -36.04M -22.87M -20.53M
Net income -40.49M -39.41M -32.55M -19.58M -18.41M
Selling general administrative 19.61M 20.01M 13.98M 9.64M 10.83M
Gross profit 6.62M 4.96M 1.72M 0.24M -
Reconciled depreciation 0.48M 0.43M 0.50M 0.48M 0.40M
Ebit -48.59M -45.81M -35.85M -22.73M -20.57M
Ebitda -47.88M -45.38M -35.22M -22.23M -20.17M
Depreciation and amortization 0.71M 0.44M 0.62M 0.51M 0.40M
Operating income -48.59M -45.81M -35.85M -22.73M -20.57M
Other operating expenses 66.09M 58.23M 41.33M 22.98M 20.57M
Interest expense 0.05M 0.01M 0.32M 0.16M 0.04M
Tax provision -6.88M -6.45M -4.60M -3.29M -2.12M
Interest income 0.23M 0.01M 1.73M 0.03M 0.04M
Net interest income 0.18M 0.00M 1.73M -0.01M 0.04M
Income tax expense -6.88M -6.45M -3.49M -3.29M -2.12M
Total revenue 17.50M 12.41M 5.48M 0.24M 0.00M
Total operating expenses 55.21M 50.77M 37.56M 22.98M 20.57M
Cost of revenue 10.88M 7.46M 3.76M - -
Total other income expense net 1.23M -0.04M -0.19M -0.14M 0.01M
Net income from continuing ops -40.49M -39.41M -22.06M -19.58M -18.41M
Net income applicable to common shares -40.49M -39.41M -32.55M -19.58M -18.41M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 93.82M 107.50M 96.19M 85.97M 46.08M
Intangible assets 0.28M 0.32M 0.02M 0.02M 0.03M
Other current assets 26.76M - 4.31M 4.62M 0.89M
Total liab 76.77M 85.43M 87.67M 76.91M 25.17M
Total stockholder equity 17.05M 22.07M 8.53M 9.06M 20.91M
Other current liab 9.80M 9.45M 6.72M 5.91M 5.10M
Common stock 5.94M 5.39M 4.49M 4.17M 3.92M
Capital stock 5.94M 5.39M 4.49M 4.17M 3.92M
Retained earnings -304.61M -263.26M -222.97M -184.22M -152.00M
Other liab - 63.48M 72.50M 51.34M 15.52M
Good will 7.84M 8.01M 7.59M 8.12M 7.69M
Cash 54.03M 54.82M 73.54M 27.45M 13.52M
Total current liabilities 17.77M 21.94M 15.17M 25.57M 9.65M
Current deferred revenue 5.16M 8.86M 4.25M 17.04M 2.48M
Net debt -53.76M -54.37M -73.40M -27.11M -13.23M
Short term debt 0.18M 0.45M 0.14M 0.34M 0.29M
Short long term debt total 0.27M 0.45M 0.14M 0.34M 0.29M
Other stockholder equity 291.52M 255.61M 203.21M 9.06M 171.94M
Property plant equipment - 2.20M 1.94M 1.13M 0.61M
Total current assets 81.02M 96.69M 86.33M 76.40M 37.47M
Long term investments 0.28M 0.28M 0.30M 0.30M -
Net tangible assets - 13.74M 0.91M 0.92M 13.18M
Short term investments 0.00M 16.33M - 10.00M 20.00M
Net receivables 18.83M 17.34M 8.49M 32.84M 3.06M
Inventory -18.61M - - 1.49M -
Accounts payable 2.63M 3.19M 4.07M 8.19M 6.89M
Accumulated other comprehensive income 24.20M 24.33M 23.79M 189.11M 168.99M
Common stock total equity - - - 4.17M 3.92M
Non currrent assets other 2.58M - - 10.00M 20.00M
Non current assets total 12.80M 10.81M 9.86M 9.57M 8.61M
Capital lease obligations 0.27M 0.45M 0.14M 0.34M 0.29M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -16.54M 10.00M -41.25M -15.02M -4.83M
Change to liabilities -3.45M 10.77M 51.69M 21.05M 1.15M
Total cashflows from investing activities -16.54M 8.68M 9.62M -15.02M -4.83M
Net borrowings -0.19M -0.21M -0.40M -0.40M -0.40M
Total cash from financing activities 43.05M 30.71M 15.43M 5.27M 0.34M
Change to operating activities -4.22M 0.59M -3.73M 0.04M -0.92M
Net income -47.37M -45.86M -36.04M -22.87M -20.53M
Change in cash -18.72M 46.09M 13.93M -7.98M -21.25M
Begin period cash flow 73.54M 27.45M 13.52M 21.49M 42.74M
End period cash flow 54.82M 73.54M 27.45M 13.52M 21.49M
Total cash from operating activities -45.46M 6.81M -10.78M 1.73M -16.76M
Issuance of capital stock 43.24M 30.92M 15.83M 5.27M 0.34M
Depreciation 0.48M 0.43M 0.50M 0.48M 0.40M
Other cashflows from investing activities 0.02M 0.01M 0.13M -0.01M 0.04M
Change to account receivables -0.58M 27.48M -29.30M -0.00M 0.69M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities -16.54M 8.68M 9.62M -15.02M -4.83M
Change to netincome 2.81M 6.94M 7.48M -0.26M 0.34M
Capital expenditures 0.44M 1.33M 0.51M 0.01M 0.19M
Change in working capital -8.26M 38.84M 18.66M 21.09M 0.91M
Stock based compensation 10.25M 8.63M 4.39M 0.58M 0.68M
Other non cash items -0.56M 0.35M -4.67M 0.14M -0.04M
Free cash flow -45.90M 5.47M -11.29M 1.72M -16.95M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SLN
Silence Therapeutics PLC		 0.01
0.05%		 19.73 - - 43.41 48.26 40.77 -20.78
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Silence Therapeutics PLC

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

72 Hammersmith Road, London, United Kingdom, W14 8TH

44 20 3457 6900

https://www.silence-therapeutics.com

109

Name Title Year Born
Mr. Craig A. Tooman M.B.A., MBA Pres, CEO & Exec. Director 1966
Ms. Rhonda L. Hellums Chief Financial Officer 1972
Dr. Giles V. Campion M.D. Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director 1954
Ms. Gem Gokmen Hopkins Head of IR & Corp. Communications NA
Dr. John Strafford Ph.D. Sr. VP of Bus. Devel., Alliance Management & New Product Devel. NA
Mr. Jørgen Wittendorff Sr. VP & Head of Manufacturing NA
Dr. Barbara A. Ruskin J.D., Ph.D. Sr. VP and Chief Intellectual Property & Innovation Officer 1960
Dr. Eric Floyd Ph.D. Sr. VP of Regulatory Affairs & Quality Assurance 1962
Dr. Marie Wikstrom Lindholm Ph.D. Sr. VP & Head of Molecular Design NA
Mr. Craig A. Tooman M.B.A. President, CEO & Executive Director 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…